PSMA-PET and mpMRI in prostate cancer patients with biochemical recurrence.

The PSMA prostate recurrence study is a multisenter prospective trial where the overal aim is to evaluate the diagnostic accuracy of 18F/68Ga-PSMA PET for detection of disease in patients with biochemical recurrence. In this preliminary analysis, we have compared the clinical imaging report of PET/CT/mpMRI to a separate evaluation of mpMRI where the radiologist was blinded to the PET results. Of 94 patients included so far, recurrent disease and/or distant metastasis was detected in 44 % (median PSA 0.4 ng/ml), according to the imaging protocol while the detection rate was 17 % for the mpMRI study scoring.